Skip to main content
. 2020 Jan 20;2020(1):CD011628. doi: 10.1002/14651858.CD011628.pub2

Comparison 9. Ustekinumab vs placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Proportion of participants achieving a 50% reduction in disease severity in the short term 1 33 Risk Ratio (M‐H, Random, 95% CI) 0.48 [0.11, 2.13]